Overview

Safety/Tolerability Study With AZD1236 in Chronic Obstructive Pulmonary Disease (COPD) Patients

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to investigate the tolerability and safety of AZD 1236 compared with placebo ("inactive substance") in COPD patients by assessment of Adverse Events, vital signs and laboratory safety assessments.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca